Summary
Biogen Inc. (BIIB) filed a Form 8-K/A on July 20, 2022, primarily to correct a minor typographical error in the header dates of a previously issued press release concerning its second-quarter 2022 results. The original press release announced Biogen's operational and financial performance for the quarter ended June 30, 2022. Investors should note that this filing is an amendment to correct a date error and does not introduce new financial results or strategic information beyond what was in the original press release. The corrected press release has been re-furnished as Exhibit 99.1. It's important for investors to understand that this specific document (the 8-K/A) is purely for a date correction and the substantive financial details would be found in the original press release it references. The filing clarifies that the revised press release is furnished, not filed, meaning it does not carry the same legal implications under certain sections of the Securities Exchange Act of 1934.
Key Highlights
- 1Biogen filed an 8-K/A on July 20, 2022, to amend a previous 8-K filing.
- 2The amendment corrects a typographical error in the header dates of the second table within the press release announcing Q2 2022 results.
- 3The original press release reported results for the second quarter ended June 30, 2022.
- 4Exhibit 99.1 contains the revised press release with the corrected dates.
- 5This filing is administrative in nature, focused solely on correcting a dating error, and does not present new financial performance data.
- 6The revised press release is furnished, not filed, limiting its liability under specific sections of the Exchange Act.